HemCon Medical Technologies

Company Summary

HemCon Medical Technologies develops and markets innovative technologies addressing wound care from closure to treatment. HemCon products are designed for medical professionals in hospital, dental and clinical settings, as well as by military and civilian first responders where rapid control of bleeding is of critical importance.

Transaction Overview

On 18 April, 2016, HemCon Medical Technologies was acquired by Tricol International Group’s 100% wholly owned Oregon based subsidiary Tricol Biomedical. Transaction included the rights to the HemCon brand name, as well as the full hemostatic antibacterial wound care product line.
HemCon will operate as Tricol Biomedical where the manufacture and distribution of HemCon products will continue uninterrupted under the HemCon brand.

Significance of the Transaction

The acquisition allows Tricol to establish entry into the wound care market and enables HemCon wound closure device access to other high growth markets such as surgical and chronic wound care.

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Strategic Advisory

HemCon Medical Technologies

Has been aquired by

The undersigned acted as exclusive advisor to HemCon Medical Technologies